WOLFGANG WINKELMAYER to Glycine
This is a "connection" page, showing publications WOLFGANG WINKELMAYER has written about Glycine.
Connection Strength
1.357
-
The Dawning of a New Day in CKD Anemia Care? J Am Soc Nephrol. 2016 Apr; 27(4):968-70.
Score: 0.461
-
Global Phase 3 programme of vadadustat for treatment of anaemia of chronic kidney disease: rationale, study design and baseline characteristics of dialysis-dependent patients in the INNO2VATE trials. Nephrol Dial Transplant. 2021 11 09; 36(11):2039-2048.
Score: 0.175
-
Cardiovascular Safety of Roxadustat in CKD Anemia: A Fig Leaf Named Noninferiority. Clin J Am Soc Nephrol. 2021 08; 16(8):1155-1157.
Score: 0.172
-
Vadadustat in Patients with Anemia and Non-Dialysis-Dependent CKD. N Engl J Med. 2021 04 29; 384(17):1589-1600.
Score: 0.169
-
Safety and Efficacy of Vadadustat for Anemia in Patients Undergoing Dialysis. N Engl J Med. 2021 04 29; 384(17):1601-1612.
Score: 0.169
-
Cardiovascular safety and efficacy of vadadustat for the treatment of anemia in non-dialysis-dependent CKD: Design and baseline characteristics. Am Heart J. 2021 05; 235:1-11.
Score: 0.163
-
Erythropoietic effects of vadadustat in patients with anemia associated with chronic kidney disease. Am J Hematol. 2022 09; 97(9):1178-1188.
Score: 0.046